Bambusa Therapeutics Investors 2026

Bambusa Therapeutics — investors and similar companies (57)

Bambusa Therapeutics's investor syndicate for 2026, drawn from verified round records: 9 distinct firms and angels appear on the cap table, including RA Capital Management, Janus Henderson Investors, Redmile Group, Invus, ADAR1 Capital Management, BVF Partners L.P.. Bambusa Therapeutics is tracked in Biotech and headquartered in Boston, United States.

The companies listed below are ranked by how much of that syndicate they share, so the overlap you see is backer-based rather than sector-based. Every investor name links to that firm's own profile with its full tracked portfolio, and every company links to its funding record.

• Verified backers on record: 9
• Total disclosed funding: $105M
• Latest tracked round: Series A (2025-02-14)
• Sector: Biotech
• Headquarters: Boston, United States

• RA Capital Management
• Janus Henderson Investors
• Redmile Group
• Invus
• ADAR1 Capital Management
• BVF Partners L.P.
• Dawn Biopharma
• Salvia GmbH
• INCE Capital
• Lycia Therapeutics — shares Janus Henderson Investors +2
• Artios Pharma — shares Invus
• Earendil Labs — shares INCE Capital
• NiKang Therapeutics — shares RA Capital Management +2
• New Amsterdam Pharma — shares BVF Partners L.P. +1
• Zentalis Pharmaceuticals — shares Redmile Group
• Sironax — shares Invus
• Windward Bio — shares RA Capital Management +1
• ShouTi — shares BVF Partners L.P. +1
• Angitia Biopharmaceuticals — shares Janus Henderson Investors +1
• ILiAD Biotechnologies — shares RA Capital Management +1
• BlossomHill Therapeutics — shares Janus Henderson Investors
• Gracell Biotechnologies — shares RA Capital Management +1
• Alterome Therapeutics — shares Invus
• LEXEO Therapeutics — shares Janus Henderson Investors
• Saluda Medical — shares Redmile Group
• Boundless Bio — shares RA Capital Management +1
• Connect Biopharmaceuticals — shares RA Capital Management
• Imbria Pharmaceuticals — shares RA Capital Management
• LifeMine Therapeutics — shares Invus
• Xeris Pharmaceuticals — shares Redmile Group
• Gritstone Oncology — shares Redmile Group
• Alentis Therapeutics — shares RA Capital Management
• Asher Bio — shares RA Capital Management +1
• Design Therapeutics — shares Janus Henderson Investors +1
• Parabilis Medicines — shares RA Capital Management +1
• Ray Therapeutics — shares Janus Henderson Investors +1
• cAMPfield Therapeutics — shares RA Capital Management
• Moderna Therapeutics — shares Invus +1
• Diagonal Therapeutics — shares RA Capital Management +1
• Kinnate Biopharma — shares Janus Henderson Investors
• Adcytherix — shares Dawn Biopharma +1
• Metagenomi — shares RA Capital Management
• ADARx Pharmaceuticals — shares Invus +1
• Tyra Biosciences — shares Janus Henderson Investors
• Talaris Therapeutics — shares Invus
• Neuron23 — shares Redmile Group
• Apogee Therapeutics — shares RA Capital Management
• Neumora Therapeutics — shares Invus
• Enliven Therapeutics — shares Janus Henderson Investors
• TScan Therapeutics — shares RA Capital Management
• Point Biopharma — shares RA Capital Management
• ProfoundBio — shares Janus Henderson Investors +1
• Black Diamond Therapeutics — shares BVF Partners L.P. +3
• Nucleix — shares RA Capital Management
• Endeavor BioMedicines — shares Invus
• Galvanize Therapeutics — shares Janus Henderson Investors
• ImCheck Therapeutics — shares Invus

Bambusa Therapeutics funding profile · All research reports